Maxitrol

Neomycin sulfate, the active ingredient in Maxitrol, is a combination antibiotic and corticosteroid presented as an ophthalmic suspension for ocular use. Together with polymyxin B sulfate and dexamethasone, it treats bacterial eye infections and inflammatory conditions in patients requiring topical therapy.

GNH USA supplies Maxitrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The formulation complies with European Union pharmacopeial standards and is approved for prescription use in multiple EU member states.

Maxitrol is indicated for several ocular infections and inflammatory conditions where bacterial contamination and inflammation coexist.

Bacterial conjunctivitis: reduces bacterial load and alleviates redness, discharge, and irritation. Keratitis: eliminates pathogenic bacteria and controls corneal inflammation to promote healing. Uveitis: suppresses intra‑ocular inflammation while providing antimicrobial coverage. Post‑operative ocular inflammation: prevents infection and diminishes postoperative swelling and pain.

Topical administration of Maxitrol may be associated with ocular adverse reactions, ranging from mild irritation to rare serious events.

Common Side Effects: - Burning or stinging sensation upon instillation. - Transient blurred vision. - Increased intraocular pressure. - Mild eye irritation or redness.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis. - Secondary ocular infection, including fungal or resistant bacterial overgrowth. - Corneal ulceration. - Cataract formation or glaucoma with prolonged corticosteroid exposure.

When prescribing Maxitrol, clinicians should observe several safety considerations to minimize risks.

Medical supervision: use only under direction of an eye care professional. Avoid viral or fungal eye infections: corticosteroid component may worsen these conditions. Monitor intraocular pressure: prolonged therapy can elevate pressure leading to glaucoma. Limit duration: restrict use to the shortest effective period to reduce steroid‑related complications. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at room temperature: keep in original container, protect from light and moisture.

Maxitrol can interact with other ophthalmic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent ophthalmic corticosteroids: additive steroid effect may increase risk of glaucoma or cataract. - Systemic immunosuppressants: may enhance susceptibility to infection. - Antiviral eye drops for herpetic keratitis: steroid component can exacerbate viral replication.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase irritation. - Topical antihistamine drops: potential for reduced anti‑inflammatory effect. - Other topical antibiotics: risk of antagonistic bacterial resistance patterns.